Skip to content
Medical Health Aged Care, Seniors Interest

Dementia is Not Just About Memory Loss

Centre for Healthy Brain Ageing (CHeBA) 3 mins read

We focus too much on memory loss in relation to dementia and not enough on difficulties with identifying emotions in social situations, according to researchers from UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) and the MARCS Institute for Brain, Behaviour and Development at Western Sydney University.

The perspective paper, published in Frontiers of Psychiatry, has highlighted the importance of assessing standard emotional responses to situations in order to improve diagnosis and management of dementia. 

Lead author and social health expert Dr Suraj Samtani said that individuals with many types of dementia can identify most emotions such as happiness, sadness, surprise and fear, but have difficulties identifying other basic or primary emotions, including disgust or anger in facial expressions, as well as sarcasm and jokes in conversations. 

“The value of assessing social cognition in older adults with dementia is to improve early intervention and treatment,” said Dr Samtani.

“It can also help identify dementia pathways for individuals from type of dementia such as frontotemporal dementia, to development of behavioural symptoms. Early signs of Alzheimer’s disease - the most common form of dementia - involve memory loss, but for other types of dementia such as frontotemporal dementia, difficulties with social cognition are often the earliest signs of change.  

Humans are inherently social beings, and having social connection is considered a basic human need. As individuals age, a variety of physical, cognitive and social changes take place, which can influence daily functioning and subsequently overall wellbeing.

Dr Samtani explained that in this context social cognition is “our ability to recognise emotions, social cues, inhibit inappropriate behaviour and act appropriately in social situations.”

Social cognition is a key component of how we function as social beings and includes the ability to understand other people’s mental states, and being able to feel and respond to what other people feel.

“Deficits in any of these social cognitive functions are a core feature of mild cognitive impairment and dementia, and may represent an early decline in cognitive function,” said Dr Samtani.

“These can manifest through behaviours such as difficulties with eye contact, behaving rudely or offensively and a clear failure to detect social cues in conversations.”

Routine social cognition assessments would ensure timely and appropriate interventions to improve social functioning and strengthen social health for individuals with dementia.

Another important factor noted in the paper is the link between social cognitive skills and the maintenance of social relationships.

Dr Joyce Siette from the MARCS Institute and senior author on the paper explained that individuals experiencing difficulty responding to social cues or having trouble reading emotions will likely become isolated and lonely.

“With recent evidence indicating that social isolation is a known modifiable risk factor for dementia, it is time to consider how we can reliably detect social cognitive deficits, as well as identify changes in them over time,” said Dr Siette.

However, identifying these deficits has many challenges, notably that there is no standard or accepted approach to measuring them. 

While social reasoning and identifying and remembering faces add great value to the assessment of social cognition, the lack of measuring skills such as eye contact, asking open ended questions, using humour, understanding puns and keeping conversations going marks a flaw in the dementia diagnosis process.

“The majority of social cognition measures have either not been rigorously developed or psychometrically validated with people experiencing cognitive changes, with social behaviour the key component that remains to be assessed properly,” said Dr Samtani.

Internationally acclaimed leaders in the ageing brain and Co-Directors of CHeBA, Professor Henry Brodaty and Professor Perminder Sachdev, said that “more work was needed to develop an effective measurement of social cognition that have functionality in the clinic.”


Contact details:

Heidi Douglass

0435 579 202

h.douglass@unsw.edu.au

Media

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.